Last reviewed · How we verify
Phosphatidylserine-Omega3
At a glance
| Generic name | Phosphatidylserine-Omega3 |
|---|---|
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy (PHASE3)
- Effects of Consumption of Phosphatidylserine on the Cognitive Function (NA)
- Efficacy Study of Vayarin in Children With Autism and Comorbid Attention Deficit Hyperactivity Disorder (ADHD) (NA)
- Omega-3 Fatty Acids and Exercise on Mobility and Cognition in Older Women (PHASE2)
- Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment (NA)
- The Efficacy and Safety of Phosphatidylserine-Omega3 in Children With Attention-Deficit/ Hyperactivity Disorder (PHASE2)
- Single Photon Emission Computed Tomography (SPECT) Imaging Study of Professional American Football Players (NA)
- The Efficacy of Phosphatidylserine-Omega3 in Elderly Subjects With Memory Impairment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phosphatidylserine-Omega3 CI brief — competitive landscape report
- Phosphatidylserine-Omega3 updates RSS · CI watch RSS
- Tel-Aviv Sourasky Medical Center portfolio CI